Based on the accumulated evidence presented in this perspective article, we encourage clinicians to consider PHOSPHO1 as a genetic sequencing target in cases of suspected HPP where mutations in ALPL cannot be identified and include it in genetic testing panels for endocrine and mineral metabolism disorders, an approach increasingly gaining in popularity (57, 64, 65). Here, ALPL is linked to hypophosphatasia.